Akari Therapeutics (AKTX) vs Jasper Therapeutics (JSPR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Jasper Therapeutics (JSPR) has outperformed Akari Therapeutics (AKTX) over the past year, losing 76.7% versus a loss of 80.1%. Over five years, AKTX leads with a -99.4% price change compared with -99.7% for JSPR. Akari Therapeutics is the larger company by market cap ($19.5 million vs $18.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKTX | JSPR |
|---|---|---|
| Share price | $8.54 | $0.5672 |
| Market cap | $19.52M | $18.87M |
| 1-day change | +0.59% | +1.29% |
| YTD return | -29.67% | -69.40% |
| 1-year return | -80.07% | -76.67% |
| 5-year return | -99.38% | -99.66% |
| EPS (TTM) | $0.00 | $-1.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $40.00 | $2.69 |
| 52-week low | $3.02 | $0.315 |
| Distance from 52-week high | -78.65% | -78.91% |
| Analyst consensus | none | none |
| Avg. price target upside | +198.59% | +3426.09% |
| Average volume | 61.08K | 1.37M |
| Shares outstanding | 2.29M | 33.27M |
| Employees | 5 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Akari Therapeutics
AKTX stock →Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About Jasper Therapeutics
JSPR stock →Jasper Therapeutics, Inc., a clinical stage biotechnology company, focuses on the design and development of therapies to treat immune-mediated diseases. It is advancing a pipeline of medicines, including KP-104, a dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other unmet need nephrology disorders; Briquilimab is an anti-KIT antibody, which has demonstrated clinical results as a conditioning agent for stem cell transplant and mast cell mediated diseases, such as chronic urticarias and allergic asthma; and KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
AKTX vs JSPR FAQ
Which is bigger, Akari Therapeutics or Jasper Therapeutics?
Akari Therapeutics (AKTX) is larger, with a market capitalization of $19.52M compared with $18.87M for Jasper Therapeutics (JSPR).
Which stock has performed better over the past year, AKTX or JSPR?
JSPR returned -76.67% over the past 12 months, compared with -80.07% for AKTX (price return, excluding dividends). Past performance does not predict future results.
Are Akari Therapeutics and Jasper Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Akari Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for Jasper Therapeutics.